9HPT (Non-dominant hand): Percentage change from Part 1 baseline to each scheduled efficacy visit in Part 2
Subgroup Analysis: Confirmed Progression of disability
ITT population

Confirmed Progressors

	Placebo to Natalizumab 300 mg	Natalizumab 300 mg	p-value (a)
Percentage change from Baseline to Week 156			
n	155	137	
Mean	26.33	23.51	0.7283
SD	79.957	60.074	

(a) p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for baseline EDSS (<=5.5 or >=6) and baseline 9HPT (non-dominant hand).

9HPT (Non-dominant hand): Percentage change from Part 1 baseline to each scheduled efficacy visit in Part 2
Subgroup Analysis: Confirmed Progression of disability
ITT population

Non Progressors

	Placebo to Natalizumab 300 mg	Natalizumab 300 mg	p-value (a)
Percentage change from Baseline to Week 156			
n	99	132	
Mean	-5.63	-1.89	0.1666
SD	14.765	24.987	

(a) p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for baseline EDSS (<=5.5 or >=6) and baseline 9HPT (non-dominant hand).